FV
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Dietary caffeine to assess CYP1A2 activity, tailor clozapine doses, and predict treatment response : genetic, epigenetic and clinical analyses | Molecular psychiatry |  | 2025 | 5 | 122 | ||
| Bioavailability of Vortioxetine After a Roux-en-Y Gastric Bypass | Obesity Surgery |  | 2020 | 268 | 1 | ||
| Genetic immune and inflammatory markers associated with diabetes in solid organ transplant recipients | American Journal of Transplantation | | 2019 | 454 | 0 | ||
| Association Between Plasma Caffeine and Other Methylxanthines and Metabolic Parameters in a Psychiatric Population Treated With Psychotropic Drugs Inducing Metabolic Disturbances | Frontiers in Psychiatry | | 2018 | 464 | 282 | ||
| Early changes of blood lipid levels during psychotropic drug treatment as predictors of long-term lipid changes and of new onset dyslipidemia | Journal of Clinical Lipidology | | 2017 | 533 | 163 | ||
| Association of genetic risk scores with body mass index in Swiss psychiatric cohorts | Pharmacogenetics and genomics | | 2016 | 571 | 0 | ||
| Association of PCK1 with Body Mass Index and Other Metabolic Features in Patients With Psychotropic Treatments | Journal of clinical psychopharmacology | | 2015 | 604 | 1 | ||
| Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments | Pharmacogenetics and genomics | | 2015 | 666 | 0 | ||
| Influence of MCHR2 and MCHR2-AS1 Genetic Polymorphisms on Body Mass Index in Psychiatric Patients and In Population-Based Subjects with Present or Past Atypical Depression | PloS one | | 2015 | 617 | 250 | ||
| Influence of CRTC1 polymorphisms on body mass index and fat mass in psychiatric patients and the general adult population | JAMA psychiatry | | 2013 | 687 | 0 |
